8th February 2018



Horizon will Host a Capital Markets Day on 20 February 2018


Cambridge, UK, 7 February 2018: Horizon Discovery Group plc (LSE: HZD) ("Horizon” or "the Group"), a global leader in gene editing and gene modulation technologies, will hold a Capital Markets Day in London for investors and sell-side analysts between 15:00 – 17:00 GMT / 10:00 – 12:00 EDT on Tuesday 20 February 2018.

The event will take place at 85 Gresham Street, London, EC2V 7NQ. Registration for those attending in person will begin at 14:30 to ensure a prompt 15:00 start. There will be a simultaneous live conference call and webcast for those unable to attend in person. The webcast, with the presentation slides, will be available at https://www.horizondiscovery.com/about-us/investor-relations and a recording will be made available shortly thereafter.

The day will include several presentations showcasing the depth and breadth of Horizon’s Management team as well as providing updates on operational progress.

The agenda, commencing at 15:00 GMT / 10:00 EDT, will include the following presentations:

  • Darrin Disley, CEO: Introduction, Group Strategy and Horizon Vision
  • Richard Vellacott, CFO: Trading Update and Path to Profit
  • Terry Pizzie, Head of Commercial: Commercial Team Structure and Strategy
  • Chris Lowe, Head of Research Operations: Research Operations Team Structure and Strategy
  • Chris Claxton, IRO and Corporate Development Lead: Capital Markets and Corporate Development Strategy
  • Tom Henley, Head of Innovation: Innovation Strategy
  • Jon Moore, Head of Translational R&D: Research Biotech Update

Please contact horizon@consilium-comms.com if you would like to attend.



For further information from Horizon Discovery Group plc, please contact:


Horizon Discovery Group plc

Darrin Disley, Chief Executive Officer

Richard Vellacott, Chief Financial Officer

Chris Claxton, VP Investor Relations

Tel: +44 (0) 1223 655 580


Numis Securities Limited (Broker and NOMAD)

Michael Meade / Freddie Barnfield

Tel: +44 (0) 207 260 1000


Consilium Strategic Communications (Financial Media and Investor Relations)

Mary-Jane Elliott / Matthew Neal / Melissa Gardiner

Tel: +44 (0) 20 3709 5701

Email: horizon@consilium-comms.com


About Horizon Discovery Group plc www.horizondiscovery.com

Horizon Discovery Group plc (LSE: HZD) ("Horizon") is a world leader in gene editing and gene modulation technologies. Horizon designs and engineers cells using its translational genomics platform, a highly precise and flexible suite of DNA editing tools (rAAV, ZFN, CRISPR and Transposon) and, following the acquisition of Dharmacon, Inc., its functional genomics platform comprising gene knockdown (RNAi) and gene expression (cDNA, ORF) tools, for research and clinical applications that advance human health. Horizon’s platforms and capabilities enable researchers to alter almost any gene or modulate its function in human or mammalian cell-lines.

Horizon offers an extensive range of catalogue products and related research services to support a greater understanding of the function of genes across all species and the genetic drivers of human disease and the development of personalised molecular, cell and gene therapies. These have been adopted by over 10,000 academic, drug discovery, drug manufacturing and clinical diagnostics customers around the globe, as well as in the Company’s own R&D pipeline.

Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange’s AIM market under the tic

Back to previous page